tradingkey.logo

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy as federal ban on mass compounding of "semaglutide" takes effect

ReutersMay 22, 2025 12:37 PM

- Novo Nordisk A/S NOVOb.CO:

  • NEW NOVO NORDISK INITIATIVES SUPPORT PATIENT ACCESS TO AUTHENTIC, FDA-APPROVED WEGOVY® AS FEDERAL BAN ON MASS COMPOUNDING OF "SEMAGLUTIDE" TAKES EFFECT

  • NOVO NORDISK A/S - ONE-TIME $199 FIRST-MONTH OFFER FOR WEGOVY THROUGH JUNE 30, 2025

  • NOVO NORDISK A/S - SELF-PAYING PATIENTS OFFERED FIRST MONTH OF WEGOVY FOR $199

  • NOVO NORDISK: FOR SUBSEQUENT MONTHS, SELF-PAY PATIENTS WILL PAY $499 PER MONTH

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI